Parc Científic de Barcelona

Parc Científic de Barcelona

Information
C/Baldiri Reixac, 4-12 y 15, 08028, Barcelona

Alzheimer's, big data, cancer, pollution, embryonic development, diabetes, gene editing, cardiovascular diseases, neurodegenerative diseases, rare diseases, immunology, artificial intelligence, nanoscience, neuroscience, new materials, robotics, AIDS / HIV, transgenics
Contact
Paula Cañal
Head of Press Office
pcanal@pcb.ub.es
693252430

If you are the contact person for this centre and you wish to make any changes, please contact us.

Contact
SMC participants
Nuno Costa-Borges

Researcher and embryologist, scientific director and CEO of Embryotools, Parc Científic de Barcelona

Contents related to this centre
Mitocondrias
rare diseases
First results on babies born with pioneering technology that reduces risk of mitochondrial disease

In 2015, the United Kingdom became the first country to pass legislation allowing the use of mitochondrial donation technology, pronuclear transfer. The technique is designed to limit, through in vitro fertilization, the transmission of mitochondrial DNA diseases in babies born to women who are at high risk, and for which there is no cure. Two studies published in the New England Journal of Medicine (NEJM) describe the results of the first treatments performed to date, from which eight babies have been born by mitochondrial donation, with reduced risk of disease.